Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery

被引：8

作者：

Le N.-B. ^{[1
]}

Kim J.-H. ^{[1
]}

机构：

[1] Division of Pelvic Medicine and Reconstructive Surgery, Department of Urology, David Geffen School of Medicine at UCLA, Frank Clark Urology Center, Los Angeles, CA, 90025, 200 Medical Plaza

来源：

Current Bladder Dysfunction Reports | 2011年 / 6卷 / 1期

关键词：

Cardiac pacemaker; Cost-effectiveness; Efficacy; InterStim; Neurogenic bladder; Neurostimulation; Overactive bladder; Peripheral nerve stimulation; Posterior tibial nerve stimulation; Pudendal nerve stimulation; Sacral nerve stimulation; Sacral neuromodulation; Safety; Urinary incontinence;

D O I：

10.1007/s11884-010-0074-3

中图分类号：

学科分类号：

摘要：

From the time that it was granted US Food and Drug Administration approval, neuromodulation has secured a firm position in the treatment algorithm for overactive bladder. With neuromodulation, physicians were able to bridge the gap between the two ends of the treatment spectrum (medical therapy and open surgery). Sacral nerve stimulation has been the most widely used form of neuromodulation. Recent modifications to its design, namely the development of the tined lead and the launching of the refined InterStim II (Medtronic, Minneapolis, MN), have made sacral nerve simulation even less invasive and more effective. While InterStim is maintaining a level of success with these advancements, peripheral means of neuromodulation are being explored. The current literature takes a closer look at posterior tibial and pudendal nerve stimulation as alternatives to sacral nerve stimulation. The field of neuromodulation is also expanding in terms of the target patient population, as it is being used to treat children, patients with neurological disease, and others. As the role of neuromodulation increases, we must continue to assess its efficacy, safety, and cost-effectiveness in comparison to other therapeutic options. © 2010 The Author(s).

引用

页码：25 / 30

页数：5

共 21 条

[1] Abrams P., Cardozo L., Fall M., Et al., The standardization of terminology of lower urinary tract function: Report from Standardisation Subcommittee of the International Continence Society, Neurourol Urodyn, 21, pp. 167-178, (2002)
[2] Kelleher C.J., Cardozo L.D., Khullar V., Et al., A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder, British Journal of Obstetrics and Gynaecology, 104, pp. 988-993, (1997)
[3] Spinelli M., Sievert K.D., Latest technologic and surgical developments in using InterStim therapy for sacral neuromodulation: Impact on treatment success and safety, Eur Urol, 54, pp. 1287-1296, (2008)
[4] Leng W.W., Chancellor M.B., How sacral nerve stimulation neuromodulation works, Urol Clin North Am, 32, pp. 11-18, (2005)
[5] Siddiqui N.Y., Wu J.M., Amundsen C.L., Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review, Neurourol Urodyn, 29, (2010)
[6] Amundsen C.L., Romero A.A., Jamison M.G., Et al., Sacral neuromodulation for intractable urge incontinence: Are there factors associated with cure?, Urology, 66, pp. 746-750, (2005)
[7] Siddiqui N.Y., Amundsen C.L., Visco A.G., Et al., Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence, J Urol, 182, pp. 2799-2804, (2009)
[8] Roth T.M., Sacral neuromodulation and cardiac pacemakers, Int Urogynecol J, 21, pp. 1035-1037, (2010)
[9] Ridout A.E., Yoong W., Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy, Int Urogynecol J Pelvic Floor Dysfunct, 21, (2010)
[10] Peters K.M., MacDiarmid S.A., Wooldridge L.S., Et al., Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial, J Urol, 178, (2009)

← 1 2 3 →